Artiva Biotherapeutics, Inc. Common Stock (NASDAQ:ARTV) — Market Cap & Net Worth
Market Cap & Net Worth: Artiva Biotherapeutics, Inc. Common Stock (ARTV)
Artiva Biotherapeutics, Inc. Common Stock (NASDAQ:ARTV) has a market capitalization of $82.80 Million ($82.80 Million) as of September 17, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #20009 globally and #4563 in its home market, demonstrating a -20.38% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Artiva Biotherapeutics, Inc. Common Stock's stock price $8.91 by its total outstanding shares 24425762 (24.43 Million). Also see balance sheet size of Artiva Biotherapeutics, Inc. Common Stoc for a full breakdown of the balance sheet.
Artiva Biotherapeutics, Inc. Common Stock Market Cap History: 2024 to 2026
Artiva Biotherapeutics, Inc. Common Stock's market capitalization history from 2024 to 2026. Data shows change from $246.21 Million to $217.63 Million (-12.88% CAGR). Also see Artiva Biotherapeutics, Inc. Common Stoc operating cash flow efficiency for how efficiently the company converts equity into cash flow.
Index Memberships
Artiva Biotherapeutics, Inc. Common Stock is a constituent of 3 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.66 Trillion | 0.00% | #568 of 976 |
|
NASDAQ Composite
IXIC
|
$41.74 Trillion | 0.00% | #1925 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.88 Trillion | 0.00% | #245 of 263 |
Weight: Artiva Biotherapeutics, Inc. Common Stock's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Artiva Biotherapeutics, Inc. Common Stock Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Artiva Biotherapeutics, Inc. Common Stock's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check Artiva Biotherapeutics, Inc. Common Stoc stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
980.92x
Artiva Biotherapeutics, Inc. Common Stock's market cap is 980.92 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2024 | $246.21 Million | $251.00K | -$58.49 Million | 980.92x | N/A |
Competitor Companies of ARTV by Market Capitalization
Companies near Artiva Biotherapeutics, Inc. Common Stock in the global market cap rankings as of September 17, 2026. Review ARTV tangible net worth ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Artiva Biotherapeutics, Inc. Common Stock by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #186 globally with a market cap of $130.44 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #353 globally with a market cap of $78.29 Billion USD.
- CSL Ltd (AU:CSL): Ranked #457 globally with a market cap of $59.82 Billion USD ( AU$84.54 Billion AUD).
- Moderna Inc (NASDAQ:MRNA): Ranked #506 globally with a market cap of $54.14 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #186 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $130.44 Billion | $514.63 |
| #353 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $78.29 Billion | $774.11 |
| #457 | CSL Ltd | AU:CSL | $59.82 Billion | AU$174.26 |
| #506 | Moderna Inc | NASDAQ:MRNA | $54.14 Billion | $143.77 |
Artiva Biotherapeutics, Inc. Common Stock Historical Marketcap From 2024 to 2026
Between 2024 and today, Artiva Biotherapeutics, Inc. Common Stock's market cap moved from $246.21 Million to $ 217.63 Million, with a yearly change of -12.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $217.63 Million | +107.69% |
| 2025 | $104.79 Million | -57.44% |
| 2024 | $246.21 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Artiva Biotherapeutics, Inc. Common Stock was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $82.80 Million USD |
| MoneyControl | $82.80 Million USD |
| MarketWatch | $82.80 Million USD |
| marketcap.company | $82.80 Million USD |
| Reuters | $82.80 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Artiva Biotherapeutics, Inc. Common Stock
Artiva Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate includes AlloNK, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as rheumatoid arthritis, systemic lupus erythematosus, lupus n… Read more